Market News AIOpen the app

Morgan Stanley still thinks highly of Monopar Therapeutics and its drug development plans.

OpinionRead the original at moomoo.com
Neutral

Morgan Stanley kept its Overweight rating on Monopar, a favorable opinion. But the update reports no new company results or changes, so it does not change Monopar's business outlook.

MNPR · Monopar Therapeutics Inc.

AI read · Neutral

The AI's read

The report gives no new trial results, sales figures, or company forecast. It repeats an analyst's view, so it does not change how Monopar's business looks.

Get alerts for MNPR

Follow Monopar Therapeutics Inc. (MNPR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MNPR
Free on the App Store and Google Play, or on the web.